High penetration compositions and uses thereof
The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for non-steroidal anti-inflammatory agents (NSAIAs), which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate.
1. A method for treating an ibuprofen-treatable condition in a subject in need thereof comprising:
transdermally administering to the subject a pharmaceutical composition,
wherein the ibuprofen-treatable condition is selected from fever, pain, and inflammation; and
wherein the pharmaceutical composition comprises a therapeutically effective amount of at least one compound of Structure 1:
or a stereoisomers, wherein:
R 1 and R 2 are independently selected from H, C 1 -C 12 alkyl, C 1 -C 12 alkyloxyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, and aryl;
R 3 is H;
X is O, S or NH;
Z is S or O;
A − is a pharmaceutically acceptable counter ion; and
n=1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
2. The method according to claim 1 , wherein A − is selected from Cl − , Br − , F − , I − , and AcO − .
3. The method according to claim 1 , wherein the condition treatable by ibuprofen is rheumatoid arthritis or osteoarthritis.
4. The method according to claim 1 , wherein the composition is formulated as a solution, suspension, spray, lotion, emulsion or gel.
5. The method according to claim 4 , wherein the composition is formulated as a spray.
6. The method according to claim 1 , wherein the subject is a human or animal.
7. The method according to claim 1 , wherein the compound is:
wherein A − is selected from Cl − , Br − , F − , I − , AcO − , acetylsalicylate, oxalate and citrate.
8. The method according to claim 7 , wherein A − is Cl − or Br − .
9. The method according to claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier selected from buffered saline, water, acetone and alcohol.
10. The method according to claim 1 , wherein the compound is:
11. The method according to claim 1 , wherein the compound is selected from:
dipropylaminoethyl 2-(p-isobutylphenyl) propionate.AcOH;
diethylaminoethyl 2-(p-isobutylphenyl) propionate.AcOH;
N-dimethylaminopropyl 2-(p-isobutylphenyl) propionamide.AcOH;
S-diethylaminoethyl 2-(p-isobutylphenyl) thiopropionat.AcOH;
N-dimethylaminoethyl 2-(p-isobutylphenyl) propionamide.AcOH;
S-dimethylaminoethyl 2-(p-isobutylphenyl) thiopropionate.AcOH;
2-(Diethylamino)ethyl-2-(4-isobutylphenyl)propionate hydrochloride; and
dimethylaminoethyl 2-(p-isobutylphenyl) propionate.AcOH.
12. A method for treating an ibuprofen-treatable condition in a subject in need thereof comprising:
applying to the subject a transdermal therapeutic application system,
wherein the ibuprofen-treatable condition is selected from fever, pain and inflammation; and
wherein the system is a bandage or a patch comprising an active substance-containing matrix layer and an impermeable backing layer, and
wherein the transdermal therapeutic application system comprises a pharmaceutical composition comprising at least one compound of Structure 1:
or a stereoisomer, wherein:
R 1 and R 2 are independently selected from H, C 1 -C 12 alkyl, C 1 -C 12 alkyloxyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, and aryl;
R 3 is H;
X is O, S or NH;
Z is S or O;
A − is a pharmaceutically acceptable counter ion; and
n=1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
13. The method according to claim 12 , wherein the system comprises an active substance reservoir which has a permeable bottom facing the skin.
14. The method according to claim 12 , wherein the system is an active substance reservoir comprising a permeable bottom facing the skin, wherein by controlling the rate of release, the system enables ibuprofen to reach therapeutic blood levels to increase effectiveness and reduce the side effects of ibuprofen.
15. The method according to claim 12 , wherein the composition further comprises a pharmaceutically acceptable carrier selected from buffered saline, water, acetone and alcohol.
16. The method according to claim 12 wherein the composition is formulated as a solution, suspension, spray, lotion, emulsion or gel.
17. The method according to claim 12 , wherein the condition treatable by ibuprofen is rheumatoid arthritis or osteoarthritis.
18. The method according to claim 12 , wherein the compound is selected from:
dipropylaminoethyl 2-(p-isobutylphenyl) propionate.AcOH;
diethylaminoethyl 2-(p-isobutylphenyl) propionate.AcOH;
N-dimethylaminopropyl 2-(p-isobutylphenyl) propionamide.AcOH;
S-diethylaminoethyl 2-(p-isobutylphenyl) thiopropionat.AcOH;
N-dimethylaminoethyl 2-(p-isobutylphenyl) propionamide.AcOH;
S-dimethylaminoethyl 2-(p-isobutylphenyl) thiopropionate.AcOH;
2-(Diethylamino)ethyl-2-(4-isobutylphenyl)propionate hydrochloride; and
dimethylaminoethyl 2-(p-isobutylphenyl) propionate.AcOH.
19. The method according to claim 12 , wherein A − is selected from Cl − , Br − , F − , I − , AcO − , acetylsalicylate, citrate, and oxalate.
20. The method according to claim 12 , wherein the compound is: